Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model.

Kambhampati S, Rajewski RA, Tanol M, Haque I, Das A, Banerjee S, Jha S, Burns D, Borrego-Diaz E, Van Veldhuizen PJ, Banerjee SK.

Mol Cancer Ther. 2013 Mar;12(3):255-63. doi: 10.1158/1535-7163.MCT-12-0777. Epub 2013 Jan 3.

2.

2-methoxyestradiol inhibits Barrett's esophageal adenocarcinoma growth and differentiation through differential regulation of the beta-catenin-E-cadherin axis.

Kambhampati S, Banerjee S, Dhar K, Mehta S, Haque I, Dhar G, Majumder M, Ray G, Vanveldhuizen PJ, Banerjee SK.

Mol Cancer Ther. 2010 Mar;9(3):523-34. doi: 10.1158/1535-7163.MCT-09-0845. Epub 2010 Mar 2.

3.

Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo.

Al-Taie OH, Graf T, Illert B, Katzenberger T, Mörk H, Kraus MR, Barthelmes HU, Scheurlen M, Seufert J.

J Gastroenterol. 2009;44(9):919-29. doi: 10.1007/s00535-009-0086-y. Epub 2009 Jun 9.

PMID:
19506796
4.

Novel 2-methoxyestradiol analogues with antitumor activity.

Tinley TL, Leal RM, Randall-Hlubek DA, Cessac JW, Wilkens LR, Rao PN, Mooberry SL.

Cancer Res. 2003 Apr 1;63(7):1538-49.

5.

Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.

Ganapathy M, Ghosh R, Jianping X, Zhang X, Bedolla R, Schoolfield J, Yeh IT, Troyer DA, Olumi AF, Kumar AP.

Clin Cancer Res. 2009 Mar 1;15(5):1601-11. doi: 10.1158/1078-0432.CCR-08-1389. Epub 2009 Feb 17.

6.

NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.

Konturek PC, Kania J, Burnat G, Hahn EG.

J Physiol Pharmacol. 2006 Dec;57 Suppl 12:15-24.

7.

Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett's esophageal adenocarcinoma.

McFadden DW, Riggs DR, Jackson BJ, Vona-Davis L.

Am J Surg. 2003 Nov;186(5):552-5.

PMID:
14599624
8.

Peptide YY inhibits the growth of Barrett's esophageal adenocarcinoma in vitro.

McFadden DW, Riggs DR, Jackson BJ, Vona-Davis L.

Am J Surg. 2004 Nov;188(5):516-9.

PMID:
15546561
9.

Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.

Zhang Q, Yu C, Peng S, Xu H, Wright E, Zhang X, Huo X, Cheng E, Pham TH, Asanuma K, Hatanpaa KJ, Rezai D, Wang DH, Sarode V, Melton S, Genta RM, Spechler SJ, Souza RF.

Gastroenterology. 2014 Feb;146(2):461-72.e6. doi: 10.1053/j.gastro.2013.10.011. Epub 2013 Oct 9.

10.
11.

Effect of estrogen on growth and apoptosis in esophageal adenocarcinoma cells.

Sukocheva OA, Wee C, Ansar A, Hussey DJ, Watson DI.

Dis Esophagus. 2013 Aug;26(6):628-35. doi: 10.1111/dote.12000. Epub 2012 Nov 16.

PMID:
23163347
12.

Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.

Edsall AB, Agoston GE, Treston AM, Plum SM, McClanahan RH, Lu TS, Song W, Cushman M.

J Med Chem. 2007 Dec 27;50(26):6700-5. Epub 2007 Dec 6.

PMID:
18052315
13.

Corn-derived carbohydrate inositol hexaphosphate inhibits Barrett's adenocarcinoma growth by pro-apoptotic mechanisms.

McFadden DW, Riggs DR, Jackson BJ, Cunningham C.

Oncol Rep. 2008 Feb;19(2):563-6.

PMID:
18202808
14.

Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.

Pratt SE, Durland-Busbice S, Shepard RL, Donoho GP, Starling JJ, Wickremsinhe ER, Perkins EJ, Dantzig AH.

Mol Cancer Ther. 2013 Apr;12(4):481-90. doi: 10.1158/1535-7163.MCT-12-0654. Epub 2013 Jan 31.

15.

Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor.

Shammas MA, Koley H, Beer DG, Li C, Goyal RK, Munshi NC.

Gastroenterology. 2004 May;126(5):1337-46.

PMID:
15131795
16.

Statins in esophageal cancer cell lines: promising lead?

Hawk ET, Viner JL.

Am J Gastroenterol. 2008 Apr;103(4):838-41. doi: 10.1111/j.1572-0241.2007.01768.x. Epub 2008 Mar 24.

PMID:
18371147
17.

Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.

Ishimura N, Amano Y, Sanchez-Siles AA, Fukuhara H, Takahashi Y, Uno G, Tamagawa Y, Mishima Y, Yuki T, Ishihara S, Kinoshita Y.

J Clin Gastroenterol. 2011 Sep;45(8):665-72. doi: 10.1097/MCG.0b013e318207f240.

PMID:
21325951
18.

Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.

Buskens CJ, Hulscher JB, van Gulik TM, Ten Kate FJ, van Lanschot JJ.

J Surg Res. 2006 Oct;135(2):337-44. Epub 2006 Aug 22.

PMID:
16926029
19.

Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.

Devy L, de Groot FM, Blacher S, Hajitou A, Beusker PH, Scheeren HW, Foidart JM, Noël A.

FASEB J. 2004 Mar;18(3):565-7. Epub 2004 Jan 20.

20.

Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.

Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, Ohmori O, Motoki T, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Beer DG, Nagatsuka H, Tanaka N, Naomoto Y.

Clin Cancer Res. 2008 Jul 15;14(14):4631-9. doi: 10.1158/1078-0432.CCR-07-4755.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk